Melfalan Hikma (Melphalan)

Melphalan exerts its antineoplastic activity by forming covalent cross‑links between DNA strands, primarily at the N7 position of guanine bases. These cross‑links prevent DNA replication and transcription, leading to cell‑cycle arrest and apoptosis of rapidly dividing tumor cells.

The dose of melphalan is individualized by the prescribing oncologist based on the specific cancer type, disease stage, patient weight, renal function and treatment protocol. Dosage regimens are determined in a clinical setting and are not standardized across all patients.

Melphalan is classified as pregnancy category D, indicating evidence of fetal risk, and it is contraindicated during pregnancy. It is also excreted in breast milk, so breastfeeding is not recommended while receiving treatment.

To request Melfalan Hikma, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with other alkylating agents such as cyclophosphamide or busulfan, melphalan has a higher potency and is often used for high‑dose regimens in hematologic malignancies. Its toxicity profile includes pronounced myelosuppression, but it may offer improved response rates in certain cancers like multiple myeloma.

Melfalan Hikma should be stored at controlled room temperature, below 25 °C, protected from light, and kept in its original packaging to maintain stability. The solution must be handled with protective gloves and prepared in a sterile environment to avoid contamination.

The product is supplied as an intravenous solution that is infused directly into a vein by a qualified healthcare professional. Administration is typically performed in a clinical setting, with infusion rates and pre‑medication (e.g., anti‑emetics) determined by the treating physician.

The most serious risks include severe myelosuppression leading to infection or bleeding, secondary malignancies, pulmonary toxicity such as interstitial pneumonitis, and renal impairment. Patients should be closely monitored for signs of infection, respiratory distress and changes in kidney function throughout treatment.

Melphalan is contraindicated in pregnant women, patients with known hypersensitivity to melphalan or related compounds, and individuals with severe renal impairment where dose adjustment is not feasible. Caution is also advised for patients with active infections or uncontrolled cardiac disease.